secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-068599
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences Q1 net loss $23.9M; cash $240.8M; Phase 2 canvuparatide data due 3Q25
--------------------------------------------------------------------------------

- Net loss $23.9M (vs $12.3M YoY); R&D $22.4M (up 103% YoY) on MBX 4291 and canvuparatide trials.
- Cash, cash equivalents & marketable securities $240.8M; expected to fund operations into mid-2027.
- Phase 2 Avail topline results for canvuparatide in hypoparathyroidism expected in 3Q 2025.
- IND submission for MBX 4291 (GLP-1/GIP co-agonist for obesity) on track for Q2 2025.
- Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia expected to start H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/0000950170-25-068599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/mbx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer